CYAD - Celyad SA

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Celyad SA

Axis Business Park
Rue Edouard Belin 2
Mont-Saint-Guibert 1435
Belgium
32 1 039 41 00
http://www.celyad.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees92

Key Executives

NameTitlePayExercisedYear Born
Mr. Michel E. LussierCo-Founder & ChairmanN/AN/A1956
Mr. Filippo Joseph PettiCEO & CFON/AN/A1972
Dr. Jean-Pierre LatereChief Operating OfficerN/AN/A1975
Nicolas Van HoeckeDirector of Investor Relations & CommunicationsN/AN/AN/A
Mr. Philippe DechampsChief Legal OfficerN/AN/A1970
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of hematological malignancies and solid tumors. The company's lead drug product candidate, CYAD-01 (CAR-T-NKG2D), an autologous chimeric antigen receptor that is in Phase I clinical trials, which expresses the NKG2D receptor from natural killer (NK) cells that binds to eight stress-induced ligands expressed on tumor cells for the treatment of patients with relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an investigational, non-gene edited allogeneic CAR-T therapy that is in Phase I trials, which co-expresses the NKG2D receptor of CYAD-01 and the inhibitory peptide Tcell receptor inhibiting molecule; and preclinical development CAR-T product candidates, such as CYAD-02 and CYAD-03 for the treatment of hematological malignancies and solid tumors. In addition, the company's short hairpin RNA-based allogeneic CAR-T candidates comprise CYAD-211, a B-cell maturation antigen targeting CAR-T candidate for the treatment of multiple myeloma; CYAD-221, a CD19 targeting CAR-T candidate for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

Corporate Governance

Celyad SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.